Skip to main content
Log in

Cardiac Lesions Induced by Testosterone: Protective Effects of Dexrazoxane and Trimetazidine

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

Further to our previous observation of post-mortem cardiac lesions after sudden death in several athletes with a history of anabolic steroid abuse, this study was intended to reproduce these lesions in rabbits administered testosterone oenanthate, a prototypic anabolic steroid abused by athletes, and to provide evidence for the protective effects of trimetazidine and dexrazoxane that are used as antianginal and cardioprotective drugs, respectively. Groups of six rabbits each were administered saline, testosterone, or a combination of testosterone and either trimetazidine or dexrazoxane for 3 months. Histologic cardiac lesions including necrosis, misshapen cell nuclei, interstitial and endocardial fibrosis, lymphocytic infiltrates, and vascular dystrophies were observed in testosterone-treated rabbits. In contrast, no significant lesions were observed in the animals treated with testosterone combined with either trimetazidine or dexrazoxane. This is the first study providing evidence for testosterone cardiotoxicity following sub-chronic exposure in laboratory animals. In addition, these results suggest the protective role of trimetazidine and dexrazoxane.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Deligiannis, A., Björnstad, H., Carre, F., Heidbüchel, H., Kouidi, E., Panhuyzen-Goedkoop, N. M., et al. (2006). ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes. European Journal of Cardiovascular Prevention and Rehabilitation, 13, 687–694. doi:10.1097/01.hjr.0000224482.95597.7a.

    Article  PubMed  Google Scholar 

  2. Kindermann, W. (2006). Cardiovascular side effects of anabolic-androgenic steroids. Herz, 31, 566–573. doi:10.1007/s00059-006-2856-0.

    Article  PubMed  Google Scholar 

  3. Di Paolo, M., Agozzino, M., Toni, C., Luciani, A. B., Molendini, L., Scaglione, M., et al. (2007). Sudden anabolic steroid abuse-related death in athletes. International Journal of Cardiology, 114, 114–117. doi:10.1016/j.ijcard.2005.11.033.

    Article  PubMed  Google Scholar 

  4. Fineschi, V., Riezzo, I., Centini, F., Silingardi, E., Licata, M., Beduschi, G., et al. (2007). Sudden cardiac death during anabolic steroid abuse: Morphologic and toxicologic findings in two fatal cases of bodybuilders. International Journal of Legal Medicine, 121, 48–53. doi:10.1007/s00414-005-0055-9.

    Article  PubMed  Google Scholar 

  5. Pärssinen, M., Kujala, U., Vartiainen, E., Sarna, S., & Seppälä, T. (2000). Increased premature mortality of competitive power lifters suspected to have used anabolic agents. International Journal of Sports Medicine, 21, 225–227. doi:10.1055/s-2000-304.

    Article  PubMed  Google Scholar 

  6. Luke, J. L., Farb, A., Virmani, R., & Sample, R. H. (1990). Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: Pathological and toxicological findings. Journal of Forensic Sciences, 35, 1441–1447.

    PubMed  CAS  Google Scholar 

  7. Maron, B. J., Epstein, S. E., & Roberts, W. C. (1986). Causes of sudden death in competitive athletes. Journal of the American College of Cardiology, 1, 204–214.

    Article  Google Scholar 

  8. Corrado, D., Basso, C., Pavei, A., Michieli, P., Schiavon, M., & Thiene, G. (2006). Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. Journal of the American Medical Association, 296, 1593–1601. doi:10.1001/jama.296.13.1593.

    Article  PubMed  CAS  Google Scholar 

  9. Fanton, L., Belhani, D., Vaillant, F., Tabib, A., Gomez, L., Descotes, J., et al. (2008). Heart lesions associated with anabolic steroid abuse: Comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. Experimental and Toxicologic Pathology, (Nov), 20. Epub ahead of print.

  10. Bertomeu-Gonzalez, V., Bouzas-Mosquera, A., & Kaski, J. C. (2006). Role of trimetazidine in management of ischemic cardiomyopathy. The American Journal of Cardiology, 98(5A), 19J–24J. doi:10.1016/j.amjcard.2006.07.005.

    Article  PubMed  CAS  Google Scholar 

  11. Wiseman, L. R., & Spencer, C. M. (1998). Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs, 56, 385–403. doi:10.2165/00003495-199856030-00009.

    Article  PubMed  CAS  Google Scholar 

  12. Hartgens, F., & Kuipers, H. (2004). Effects of androgenic-anabolic steroids in athletes. Sports Medicine (Auckland, N.Z.), 34, 513–554. doi:10.2165/00007256-200434080-00003.

    Article  Google Scholar 

  13. Rossi, M. A. (1991). Patterns of myocardial fibrosis in idiopathic cardiomyopathies and chronic Chagasic cardiopathy. The Canadian Journal of Cardiology, 7, 287–294.

    PubMed  CAS  Google Scholar 

  14. Cavasin, M. A., Tao, Z. Y., Yu, A. L., & Yang, X. P. (2006). Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. American Journal of Physiology. Heart and Circulatory Physiology, 290, 2043–2050. doi:10.1152/ajpheart.01121.2005.

    Article  CAS  Google Scholar 

  15. Wang, M., Tsai, B. M., Kher, A., Baker, L. B., Wairiuko, G. M., & Meldrum, D. R. (2005). Role of endogenous testosterone in myocardial proinflammatory and proapoptotic signaling after acute ischemia-reperfusion. American Journal of Physiology. Heart and Circulatory Physiology, 288, H221–H226. doi:10.1152/ajpheart.00784.2004.

    Article  PubMed  CAS  Google Scholar 

  16. Inoue, H., Nishida, N., Ikeda, N., Tsuji, A., Kudo, K., Hanagama, M., et al. (2007). The sudden and unexpected death of a female-to-male transsexual patient. Journal of Forensic and Legal Medicine, 21, 1–7.

    Google Scholar 

  17. Hartgens, F., Cheriex, E. C., & Kuipers, H. (2003). Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. International Journal of Sports Medicine, 24, 344–351. doi:10.1055/s-2003-40705.

    Article  PubMed  CAS  Google Scholar 

  18. Gauthier, J. (2001). Cardiovascular effects of doping. Annales de Cardiologie et d’Angeiologie, 50, 293–298. doi:10.1016/S0003-3928(01)00032-4.

    Article  PubMed  CAS  Google Scholar 

  19. Ren, G., Dewald, O., & Frangogiannis, N. G. (2003). Inflammatory mechanisms in myocardial infarction. Current Drug Targets. Inflammation and Allergy, 2, 242–256. doi:10.2174/1568010033484098.

    Article  PubMed  CAS  Google Scholar 

  20. Meldrum, D. R., Wang, M., Tsai, B. M., Kher, A., Pitcher, J. M., Brown, J. W., et al. (2005). Intracellular signaling mechanisms of sex hormones in acute myocardial inflammation and injury. Frontiers in Bioscience, 10, 1835–1867. doi:10.2741/1665.

    Article  PubMed  CAS  Google Scholar 

  21. Argaud, L., Gomez, L., Gateau-Roesch, O., Couture-Lepetit, E., Loufouat, J., Robert, D., et al. (2005). Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. Journal of Molecular and Cellular Cardiology, 39, 893–899. doi:10.1016/j.yjmcc.2005.09.012.

    Article  PubMed  CAS  Google Scholar 

  22. Kajstura, J., Liu, Y., Baldini, A., Li, B., Olivetti, G., Leri, A., et al. (1998). Coronary artery constriction in rats: necrotic and apoptotic myocyte death. The American Journal of Cardiology, 82, 30K–41K. doi:10.1016/S0002-9149(98)00535-9.

    Article  PubMed  CAS  Google Scholar 

  23. Ruixing, Y., Wenwu, L., & Al-Ghazali, R. (2007). Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Translational Research; the Journal of Laboratory and Clinical Medicine, 149, 152–160. doi:10.1016/j.trsl.2006.11.004.

    PubMed  Google Scholar 

  24. Paiva, M. G., Petrilli, A. S., Moises, V. A., Macedo, C. R., Tanaka, C., & Campos, O. (2005). Cardioprotective effect of dexrazoxane during treatment with doxorubicin: A study using low-dose dobutamine stress echocardiography. Pediatric Blood & Cancer, 45, 902–908. doi:10.1002/pbc.20488.

    Article  Google Scholar 

  25. Chen, B., Peng, X., Pentassuglia, L., Lim, C. C., & Sawyer, D. B. (2007). Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovascular Toxicology, 7, 114–121. doi:10.1007/s12012-007-0005-5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jacques Descotes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belhani, D., Fanton, L., Vaillant, F. et al. Cardiac Lesions Induced by Testosterone: Protective Effects of Dexrazoxane and Trimetazidine. Cardiovasc Toxicol 9, 64–69 (2009). https://doi.org/10.1007/s12012-009-9041-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-009-9041-7

Keywords

Navigation